{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:42:30Z","timestamp":1790793750135,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019543","name":"Kristen Ann Carr Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.esmoop.2026.106899","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:07:03Z","timestamp":1774037223000},"page":"106899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated\/dedifferentiated liposarcoma"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7222-781X","authenticated-orcid":false,"given":"O.O.","family":"Babatunde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Seier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Keohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.P.","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Gounder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9717-8205","authenticated-orcid":false,"given":"C.R.","family":"Antonescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5437-4951","authenticated-orcid":false,"given":"J.","family":"Landa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.-X.","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Crago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Koff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.D.","family":"Tap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.106899_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/483154","article-title":"Liposarcoma: molecular genetics and therapeutics","volume":"2011","author":"Conyers","year":"2011","journal-title":"Sarcoma"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106899_bib2","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1097\/PAS.0b013e3180581fff","article-title":"Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR","volume":"31","author":"Sirvent","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"28","key":"10.1016\/j.esmoop.2026.106899_bib3","doi-asserted-by":"crossref","first-page":"19891","DOI":"10.18632\/oncotarget.24924","article-title":"Targeted next generation sequencing of well-differentiated\/dedifferentiated liposarcoma reveals novel gene amplifications and mutations","volume":"9","author":"Somaiah","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2026.106899_bib4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.14694\/EdBook_AM.2015.35.213","article-title":"Application of molecular biology to individualize therapy for patients with liposarcoma","author":"Manji","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106899_bib5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.soc.2016.05.007","article-title":"Liposarcoma: multimodality management and future targeted therapies","volume":"25","author":"Crago","year":"2016","journal-title":"Surg Oncol Clin N Am"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106899_bib6","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/SLA.0000000000001447","article-title":"Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS working group","volume":"263","author":"Gronchi","year":"2016","journal-title":"Ann Surg"},{"issue":"18","key":"10.1016\/j.esmoop.2026.106899_bib7","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1016\/j.ejca.2005.07.023","article-title":"Differential sensitivity of liposarcoma subtypes to chemotherapy","volume":"41","author":"Jones","year":"2005","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106899_bib8","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdr485","article-title":"Advanced well-differentiated\/dedifferentiated liposarcomas: role of chemotherapy and survival","volume":"23","author":"Italiano","year":"2012","journal-title":"Ann Oncol"},{"issue":"10028","key":"10.1016\/j.esmoop.2026.106899_bib9","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106899_bib10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2026.106899_bib11","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2012.46.5476","article-title":"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma","volume":"31","author":"Dickson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106899_bib12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaoncol.2016.0264","article-title":"Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial","volume":"2","author":"Dickson","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106899_bib13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1158\/1078-0432.CCR-23-2378","article-title":"Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma","volume":"30","author":"Gleason","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.106899_bib14","article-title":"SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma","volume":"41","author":"Dickson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"37","key":"10.1016\/j.esmoop.2026.106899_bib15","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1038\/s41388-018-0332-y","article-title":"PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4\/6 inhibitor therapy-induced senescence","volume":"37","author":"Klein","year":"2018","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106899_bib16","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/ijc.33956","article-title":"Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center","volume":"150","author":"Nassif","year":"2022","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106899_bib17","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1038\/s41598-025-85937-9","article-title":"Survival and prognostic factors among different types of liposarcomas based on SEER database","volume":"15","author":"Zhao","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106899_bib18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12885-017-3398-y","article-title":"Prognostic factors and outcome of liposarcoma patients: a retrospective evaluation over 15 years","volume":"17","author":"Knebel","year":"2017","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106899_bib19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jamcollsurg.2013.10.009","article-title":"Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery","volume":"218","author":"Keung","year":"2014","journal-title":"J Am Coll Surg"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106899_bib20","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cncr.31927","article-title":"Radiotherapy for retroperitoneal liposarcoma: a report from the Transatlantic Retroperitoneal Sarcoma Working Group","volume":"125","author":"Haas","year":"2019","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106899_bib21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.prro.2021.04.005","article-title":"Radiation therapy for treatment of soft tissue sarcoma in adults: executive summary of an ASTRO clinical practice guideline","volume":"11","author":"Salerno","year":"2021","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106899_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/000313481908500126","article-title":"Radiation and its impact on local recurrence in extremity and trunk well-differentiated liposarcomas","volume":"85","author":"Fonseca","year":"2019","journal-title":"Am Surg"},{"issue":"7668","key":"10.1016\/j.esmoop.2026.106899_bib23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106899_bib24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.106899_bib25","article-title":"1720MO A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma","volume":"35","author":"Rosenbaum","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106899_bib26","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.18632\/oncotarget.3364","article-title":"MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition","volume":"6","author":"Kovatcheva","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106899_bib27","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-21-1291","article-title":"Co-targeting of MDM2 and CDK4\/6 with siremadlin and ribociclib for the treatment of patients with well-differentiated or dedifferentiated liposarcoma: results from a proof-of-concept, phase Ib study","volume":"28","author":"Abdul Razak","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:11:40Z","timestamp":1777623100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926008410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2059702926008410"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106899","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated\/dedifferentiated liposarcoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106899"}}